{"nctId":"NCT04247074","briefTitle":"Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination","startDateStruct":{"date":"2020-02-10","type":"ACTUAL"},"conditions":["Glabellar Frown Lines (GL)","Lateral Canthal Lines (LCL)"],"count":413,"armGroups":[{"label":"QM1114-DP in the LCL + Placebo in the GL","type":"EXPERIMENTAL","interventionNames":["Biological: botulinum toxin neuromodulator","Biological: Placebo"]},{"label":"Placebo in the LCL and GL","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo"]},{"label":"Placebo in the LCL + QM1114-DP in the GL","type":"EXPERIMENTAL","interventionNames":["Biological: botulinum toxin neuromodulator","Biological: Placebo"]},{"label":"QM1114-DP in the LCL + GL","type":"EXPERIMENTAL","interventionNames":["Biological: botulinum toxin neuromodulator"]}],"interventions":[{"name":"botulinum toxin neuromodulator","otherNames":["QM1114-DP"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male or female 18 years of age or older.\n2. Moderate to severe LCL at maximum smile as assessed by the Investigator.\n3. Moderate to severe LCL at maximum smile as assessed by the subject.\n4. Moderate to severe GL at maximum frown as assessed by the Investigator.\n5. Moderate to severe GL at maximum frown as assessed by the subject\n\nExclusion Criteria:\n\n1. Previous use of any Botulinum toxin in facial areas within 9 months prior to study treatment.\n2. Female who is pregnant, breast feeding, or intends to conceive a child during the study.\n3. Known allergy or hypersensitivity to any component of the investigational product (QM1114-DP).","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects With a ≥ 2-grade Improvement From Baseline on the Glabellar Lines Investigator and Subject Assessments at Maximum Frown","description":"Investigator 4-point Photographic Scale of Glabellar Line Severity represents the severity of GL from none (grade 0), mild (grade 1), moderate (grade 2) to severe (grade 3). Each grade is depicted by an individual photograph and a descriptive text. The Investigators used the 4-point Photographic Scale for direct, live comparison with the subject's face at maximum frown.\n\nSubjects made their assessment of glabellar line severity independently of the Investigator's assessment. Subjects were asked to evaluate their GL at maximum frown by grading the GL severity from none (grade 0, smooth skin), mild (grade 1, fairly smooth skin), moderate (grade 2, frown lines) to severe (grade 3, deep frown lines).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"75","spread":null},{"groupId":"OG002","value":"78","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects With a ≥ 2-grade Improvement From Baseline on the Lateral Canthal Lines Investigator and Subject Assessments at Maximum Smile","description":"Investigator 4-point Photographic Scale of Lateral Canthal Line represents LCL severities from none (grade 0), mild (grade 1), moderate (grade 2), to severe (grade 3). Each grade is also depicted by an individual photograph and descriptive text. The Investigators used the LCL-ILA for direct, live comparison with the subject's face for grading LCL severity. Left and right LCL were assessed at maximum smile.\n\nSubject 4-point Photographic Scale of Lateral Canthal Line Severity represents LCL severities from Level 0, Level 1, Level 2, to Level 3. Each grade is also depicted by an individual photograph and descriptive text. Subjects made their assessments independently of the Investigator's assessment. Subjects evaluated their LCL severity (left and right side separately) at maximum smile.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"59","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With a 0 or 1 on the Glabellar Lines Investigator Scale at Maximum Frown","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"97","spread":null},{"groupId":"OG002","value":"102","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Who Achieve Grade 0 or 1 in Lateral Canthal Line Investigator Scale at Maximum Smile.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"89","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":123},"commonTop":["COVID-19","Headache","Injection site bruising","Eyelid ptosis","Injection site pain"]}}}